TNFSF10 and cancer: In this report, based on a 24-base-pair deletion mutant E1A oncolytic Ad (Δ24E1A) [27–29], we outlined the biochemical analysis, functional validation and anti-tumor activity of a novel TRAIL-modified Ad vector and demonstrated that this engineered Ad virion with TRAIL on the surface could target cancer tissues administered by IV injection in vivo.